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Abstract
Background: Exposure to inorganic arsenic (As) through drinking water during pregnancy is associated with lower
birth size and child growth. The aim of the study was to assess the effects of As exposure on child growth
parameters to evaluate causal associations.
Methodology/Findings: Children born in a longitudinal mother-child cohort in rural Bangladesh were studied at 4.5
years (n=640) as well as at birth (n=134). Exposure to arsenic was assessed by concurrent and prenatal (maternal)
urinary concentrations of arsenic metabolites (U-As). Associations with plasma concentrations of insulin-like growth
factor 1 (IGF-1), calcium (Ca), vitamin D (Vit-D), bone-specific alkaline phosphatase (B-ALP), intact parathyroid
hormone (iPTH), and phosphate (PO4) were evaluated by linear regression analysis, adjusted for socioeconomic
factor, parity and child sex. Child U-As (per 10 µg/L) was significantly inversely associated with concurrent plasma
IGF-1 (β=-0.27; 95% confidence interval: -0.50, -0.0042) at 4.5 years. The effect was more obvious in girls (β=-0.29;
-0.59, 0.021) than in boys, and particularly in girls with adequate height (β=-0.491; -0.97, -0.02) or weight (β=-0.47;
0.97, 0.01). Maternal U-As was inversely associated with child IGF-1 at birth (r=-0.254, P=0.003), but not at 4.5
years. There was a tendency of positive association between U-As and plasma PO4 in stunted boys (β=0.27; 0.089,
0.46). When stratified by % monomethylarsonic acid (MMA, arsenic metabolite) (median split at 9.7%), a much
stronger inverse association between U-As and IGF-1 in the girls (β=-0.41; -0.77, -0.03) was obtained above the
median split.
Conclusion: The results suggest that As-related growth impairment in children is mediated, at least partly, through
suppressed IGF-1 levels.
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Introduction
Exposure to As during pregnancy has been associated with
pre-term births and increased risks of fetal and infant mortality
[1-4]. Elevated arsenic concentrations in drinking water have
also been associated with lower birth weight [2,5]. In our
ongoing population-based mother-child cohort study in rural
Bangladesh, we detected lower size at birth in relation to
relatively low levels of arsenic exposure during pregnancy
(<100 µg/L in maternal urine) [6,7]. The inverse associations
between maternal As exposure and fetal size, measured by
ultrasound in early and late pregnancy, were most obvious for
the head measures and femur length [6]. The effects on child
growth remained until 5 years of age and were aggravated by
continuous exposure after the breast-feeding period [8]
{Gardner, 2013 #742}.
Arsenate (AsV) is known to accumulate in bone, due to its
chemical similarities to PO4 [9], while trivalent arsenic has been
found to inhibit cartilage formation in chick limb bud
mesenchymal culture [10]. In animal studies, offspring exposed
to high arsenic doses in utero had reduced fetal weight and
increased frequency of axial skeletal malformations [11,12],
effects that were accentuated by protein deficiency [13].
Furthermore, experimental animals exposed to As in drinking
water showed alteration in endochondral ossification during
bone remodeling [14].
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In this study, we aimed to elucidate the mechanisms involved
in arsenic-related fetal and child growth impairment, using
biochemical indicators of bone development and growth.
Specifically for growth, we assessed the IGF-1 hormone, which
is a crucial mediator of body size, embryonic and postnatal
development, and affects skeletal muscle, cartilage and bone.
We hypothesized that in addition to the concurrent exposure,
prenatal exposure would contribute to an accumulating effect of
continued As exposure on child growth. Studying the prenatal
and concurrent arsenic exposure would thus allow deciphering
the early and later effects of As on the biomarkers of growth.
Results
Demographic data and As exposure
The average height and weight of the children at 4.5 years of
age were 100 cm and 14.0 kg respectively with a male to
female ratio of 51:49 (Table 1). Among the children with low
birth weight (< 2500 g), 61 were boys and 89 girls. There were
more stunted and underweight girls than boys (P=0.035 and
0.045 respectively). In the prenatal cohort, the average age of
pregnant women (n=134) was 25.6 years at enrolment and the
average gestational age at delivery was 39.3 weeks (Table 1).
Of the 134 births, 25 infants (13 boys and 12 girls) were of low
birth weight. All women were non-smokers; however, 7% of the
women reported chewing tobacco. The median U-As in
mothers at gestational week 8 (GW8) was 78 µg/L and at
GW30 was 71 µg/L and in 4.5 year old children it was slightly
lower, 57 µg/L (Table 1).
Plasma Biomarkers
Descriptive statistics of all analyzed plasma biomarkers are
presented in Table 2. In spearman correlation plasma IGF-1
levels were positively associated with plasma Ca (r=0.171,
P=0.06) and vitamin D levels (r=0.181, P=0.04) in newborns,
but not at 4.5 yrs of age (r=0.002, P=0.96; r=0.013, P=0.743
respectively). Plasma PO4 concentration in 4.5 years old
children correlated positively with PTH levels (r=0.109,
P=0.006) and inversely with B-ALP (r=-0.187, P=0.0001).
There was a positive association between plasma B-ALP and
IGF-1 levels (r=0.111, P=0.005) in children. Girls had
significantly higher IGF-1 and B-ALP levels in plasma
compared to boys (Table 2). No significant difference in cord
plasma biomarkers was observed in newborn boys and girls.
Arsenic exposure, child growth and plasma biomarkers
Child plasma IGF-1 levels correlated significantly with child
height (rs=0.24; p<0.001) and weight (rs=0.17; p<0.001).
Further evaluation of the basic characteristics of the children in
relation to IGF-1 (median split at 59 μg/L) showed significantly
lower height, weight, HAZ and WAZ (i.e. higher percentage of
stunted and underweight children) with lower IGF-1 levels
(Table 3). Such differences were, however, not found in the
neonates. Both boys and girls with IGF-1 levels below 59 μg/L
had significantly lower height, weight and HAZ, but not WAZ
compared to those above the median split (Table S1 in File
S1). Mean IGF-1 levels were significantly lower in stunted
(Figure 1A) and underweight (Figure 1B) children compared to
children with normal height and weight. No associations were
Table 1. Characteristics of the study cohorts.
Variables Child cohort (N=640)
Prenatal cohort
(N=134)
4.5 years old children 
Height, cm 100 ± 4  
Weight, kg 13.9 ± 1.6  
HAZ -1.57 (-2.98; -0.11)  
Stunted, n (%) 185 (29)  
Stunted Girls, n (%) 102 (33)  
Stunted Boys, n (%) 83 (26)  
WAZ -1.80 (-3.08; -0.42)  
Underweight, n (%) 252 (39)  
Underweight Girls, n (%) 135 (43)  
Underweight Boys, n (%) 117 (36)  
Urinary As, µg/La 57 (21; 377)  
iAs, %b 8.7 ± 3.06  
MMA, %b 9.9 ± 3.4  
DMA, %b 81.3 ± 5.2  
Maternal characteristics 
Age at recruitment, years 26.6 ± 5.8 25.6 ± 5.3
BMI at GW8, kg/m2 20.4 ± 2.9 20.3 ± 2.9
Maternal education, years at school, n (%) 
No education 164 (25) 29 (22)
<5 years 71 (11) 14 (10)
≥5 - <10 years 305 (47) 62 (46)
≥ 10 years 100 (15) 29 (22)
SES quintiles, n (%)
1 poorest 90 (14) 19 (15)
2 112 (18) 17 (12)
3 141 (22) 26 (19)
4 160 (25) 40 (30)
5 richest 137 (21) 32 (24)
Parity 1.34 ± 1.2 1.14 ± 1.2
Primiparous; n (%) 209 (33) 50 (37)
Multiparous; n (%) 431 (67) 84 (63)
Tobacco chewing during
pregnancy, Yes/No; n (%) 49 (7)/591(93) 8 (7)/126(93)
U-As GW8, µg/La 78 (20; 640) 78 (20; 447)
iAs, %b 14.9 ± 8.6 n.a.
MMA, %b 9.9 ± 4.9 n.a.
DMA, %b 75.1 ± 10.5 n.a.
U-As GW30, µg/La n.a. 71 (20; 535)
Newborns 
Gestational age at birth weeks 39.3 ± 1.9 39.3 ± 2.5
Birth weight, g 2746 ± 404 2820 ± 411
Low birth weight (<2500 g), n (%) 157 (25) 25 (19)
Birth length, cm 47.6 ± 2.1 48.1 ± 2.1
Boys/girls, n (%) 328 (51)/312(49) 71 (53)/63(47)
BMI, Body Mass Index; GW, Gestational week, HAZ, height-for-age z-score; WAZ,
weight-for-age z-score; U-As; urinary arsenic. Data given as mean ± standard
deviation, median (5; 95 percentiles), or n (%). aAdjusted to average specific
gravity of 1.012 g/mL; bPercent of total metabolite concentration in urine.
doi: 10.1371/journal.pone.0081530.t001
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obtained between growth indicators and other plasma
biomarkers.
When IGF-1 levels were compared between the lowest (<35
ug/L) v.s. the highest quartile (>125.5 ug/L) of U-As in 4.5 year
old children, a significant reduction of IGF-1 levels were noted
in the 4th quartile compared to the 1st quartile (P=0.05) (Figure
1C). There was a tendency of negative association between U-
As and height (r=-0.067, P=0.08) and weight (r=-0.051,
P=0.08) of children at 4.5 years of age.
In the linear regression analyses, concurrent U-As in
children, but not prenatal arsenic, was inversely associated
with child plasma IGF-1 at 4.5 years of age (Table 4; Figure 2A
& B). The association remained fairly stable after adjustment
for socioeconomic status (SES), parity (birth order), child sex,
HAZ, and plasma levels of adjusted calcium (Adj Ca), Vit-D,
PTH, B-ALP and PO4. None of the other plasma biomarkers
showed significant associations with child U-As or maternal U-
As during pregnancy. When stratified by sex, the association
between child U-As and plasma IGF-1 was significant in girls
only (Table 4). Plasma PO4 concentrations were significantly
positively associated with U-As in boys.
In the adjusted linear regression analyses stratified by
stunting or underweight, U-As (per 10 µg/L) at 4.5 years was
significantly inversely associated with plasma IGF-1 levels
among children with normal height (β=-0.39;CI: -0.72, -0.07) or
normal weight (β=-0.34; CI: -0.60, 0.005), but not in the stunted
Table 2. Descriptive statistics of plasma growth biomarkers
in children at 4.5 years of age and in cord blood, stratified
by sex.
Variables 4.5 years (N=640) Cord blood (N=134)
 Boys (N=328) Girls (N=312) Boys (N=71) Girls (N=63)
IGF, µg/L
Mean ± SD 64 ± 41 72 ±37* 33 ± 16 38 ± 23
Median (5; 95
per) 53 (19; 135) 64 (23; 147) 31 (13; 59) 36 (8.1; 73)
Adj Ca, mg/dL
Mean 7.7 ± 2.7 7.7 ± 3.1 5.3 ± 3.2 4.3 ± 2.8
Median 7.1 (4.6; 13.4) 7.1 (4.6; 13.2) 4.6 (1.1; 12.0) 3.3 (0.71; 10.2)
Vitamin D, nmol/L
Mean 71 ± 24 70 ± 22 64 ± 29 68 ± 26
Median 68 (40; 118) 67 (41; 111) 59 (28; 133) 60 (36; 123)
PTH, ng/L
Mean 44 ± 24 44 ± 20 5.0 ± 10.3 3.7 ± 5.4
Median 40 (20; 78) 40 (20; 80) 1.2 (1.1; 29) 1.2 (0.46; 20)
B-ALP, ug/L
Mean 104 ± 50 114 ± 55* 17 ± 5.9 18 ± 8.9
Median 91 (47; 195) 101 (49; 217) 15 (10.4; 27) 16 (9.1; 41)
PO4, mg/dL
Mean 21 ± 8 21 ± 7 25 ± 19 25 ± 16
Median 20 (12; 37) 20(13; 33) 17 (11; 79) 18 (12; 59)
IGF-1, Insulin-like growth factor 1; Adj Ca, albumin adjusted calcium; Vit-D, Vitamin
D; PTH, Parathyroid hormone; B-ALP, Bone-specific alkaline phosphatase; PO4,
phosphate. * indicates P<0.05 (Mann-Whitney U test) in comparing parameters
between boys and girls.
doi: 10.1371/journal.pone.0081530.t002
or underweight children (Table 5). When children with normal
height were further stratified by sex, a significant inverse
association between U-As and IGF-1 and a positive association
between U-As and plasma Ca levels were found in girls only
(Table 5). Similarly, when children with normal weight were
stratified by sex, a significant inverse association was found
between U-As and IGF-1 in only girls. In accordance with this,
when stratified by SES, a similar association was found in
children with high SES, particularly in girls.
To evaluate the combined effects of prenatal and concurrent
exposure, we entered both exposures in the same model
(although both exposures were correlated) with other adjusting
covariates, and found that only concurrent (but not prenatal)
exposure was significant in the model. In this case, the
estimate for concurrent exposure increased about 8% (data not
shown).
The analyses stratified by sex showed stronger positive
associations between child U-As and plasma PO4 levels in
stunted or underweight boys compared to those with normal
Table 3. Basic characteristics of 4.5 years old children and
newborns in relation to plasma IGF-1 (median split at 59
µg/L).
cChildren 4.5 years
(N=640)
IGF ≤59, µg/L
(N=321)
IGF >59, µg/L
(N=319)
P value
(Mann-
Whitney U)
Height, Cm 99 ± 3.9 101 ± 3.9 <0.001
Weight, Kg 13.6 ± 1.4 14.1 ±1.7 <0.001
HAZ -1.78 (-3.15; -0.35) -1.44 (-2.73;0.002) <0.001
WAZ -1.92 (-3.19; -0.56) -1.62 (-2.96; -0.25) <0.001
Stunted, n (%) 125 (39.4) 60 (18.8) <0.001
Underweight, n (%) 142 (44.3) 110 (34.3) 0.012
U-As, µg/La 59 (21; 411) 56 (21; 324) 0.20
iAs, %b 8.7 ± 3.1 8.8 ± 3.1 0.33
DMA, % b 81.6 ± 5.1 80.9 ± 5.4 0.09
MMA, % b 9.6 ± 3.4 10.2 ± 3.5 0.04
dNewborns (N=134) IGF ≤32, µg/L(N=68)
IGF >32, µg/L
(N=66)  
BW, g 2789 ± 427 2852 ± 395 0.30
BL, cm 47.8 ± 2.3 48.3 ± 1.9 0.11
HC, cm 31.9 ± 1.5 32.1 ± 1.5 0.51
CC, cm 31.3 ± 1.8 31.4 ± 2.1 0.46
U-As at GW8, µg/La 85 (24; 443) 72 (17; 512) 0.13
iAs, % b 14.9 ± 5.3 13.7 ± 7.9 0.07
DMA, % b 75.0 ± 8.0 76.2 ± 9.2 0.33
MMA, % b 10.0 ± 4.1 10.1 ± 3.9 0.77
U-As at GW30, µg/La 108 (21; 625) 63 (16; 562) 0.04
HAZ, height-for-age z-score; WAZ, weight-for-age z-score; U-As; urinary arsenic;
BW, birth weight; BL, birth length; HC, head circumference; CC, chest
circumference. Data given as mean ± standard deviation, median (5; 95
percentiles), or n (%). aAdjusted to average specific gravity of 1.012 g/mL.
bPercent of total metabolite concentration in urine. cChildren at 4.5 years of age in
relation to children blood IGF-1. dNewborn characteristic in relation to cord blood
IGF-1.
doi: 10.1371/journal.pone.0081530.t003
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Figure 1.  Mean insulin-like growth factor 1 (IGF-1) levels in (A) stunted (N=185) and normal height (N=455); (B)
underweight (N=252) and normal weight (N=388).  (; and (C) in different quartiles of urinary arsenic (N= 160 in each quartiles) in
children at 4.5 years of age.
doi: 10.1371/journal.pone.0081530.g001
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Table 4. Linear regression analysis of plasma biomarkers in
relation to concurrent and prenatal arsenic exposure in all
children, boys and girls at 4.5 years age.
Variables U-As at 4.5 years (per 10 µg/L)
U-As at GW8 (per
10µg/L)
 Unadjusted Adjusted Adjusted
 β (95% CI) P β (95% CI) P β (95% CI) P
All children (N=640)
IGF-1, µg/La - 0.24 (-0.48,-0.006) 0.044
-0.24 (-0.46,
-0.02) 0.03
-0.004 (-0.11,
0.11) 0.94
IGF-1, µg/Lb - 0.24 (-0.46,-0.006) 0.044
-0.27 (-0.50,
-0.042) 0.02
-0.008 (-0.12,
0.10) 0.89
Adj Ca,
mg/dLa
0.009 (-0.007,
0.027) 0.25
0.007
(-0.009,
0.025)
0.36
0.004
(-0.005,
0.012)
0.42
Vit-D,
nmol/La
0.098 (-0.029,
0.22) 0.13
0.081
(-0.049,
0.201)
0.22
0.0023
(-0.068,
0.072)
0.94
PTH, ng/La -0.01 (-0.13,0.11) 0.86
-0.016 (-0.13,
0.109) 0.81
0.028
(-0.038,
0.094)
0.40
B-ALP, µg/La 0.098 (-0.19,0.38) 0.50
0.084 (-0.21,
0.37) 0.57
-0.006 (-0.16,
0.15) 0.94
PO4, mg/dLa
0.023 (-0.02,
0.06) 0.30
0.020
(-0.023,
0.064)
0.36
0.013
(-0.011,
0.037)
0.27
Boys (N=328)
IGF-1, µg/La -0.21 (-0.58,0.15) 0.25
-0.23 (-0.57,
0.12) 0.20
-0.031 (-0.21,
0.15) 0.74
IGF-1, µg/Lb -0.21 (-0.58,0.15) 0.25
-0.26 (-0.61,
0.10) 0.15
-0.041 (-0.22,
0.14) 0.65
Adj Ca,
mg/dLa
-0.007
(-0.017¸
0.032)
0.56
0.007
(-0.018,
0.032)
0.58
-0.0026
(-0.015,
0.009)
0.67
Vit-D,
nmol/La
0.031 (-.018,
0.25) 0.77
0.018 (-0.20,
0.23) 0.87
0.047
(-0.065, 0.15) 0.41
PTH, ng/La 0.076 (-0.13,0.29) 0.48
0.067 (-0.14,
0.28) 0.54
0.052
(-0.052, 0.15) 0.32
B-ALP, µg/La 0.20 (-0.25,0.65) 0.37
0.20 (-0.25,
0.65) 0.38
0.14 (-0.08,
0.37) 0.21
PO4, mg/dLa 0.088 (-0.010,0.16) 0.02
0.085 (0.007,
0.16) 0.03
0.031
(-0.008,
0.071)
0.12
Girls (N=312)
IGF-1, µg/La -0.27 (-0.56,0.01) 0.05
-0.27 (-0.54,
0.011) 0.06
0.010 (-0.13,
0.15) 0.89
IGF-1, µg/Lb -0.27 (-0.56,0.01) 0.05
-0.29 (-0.59,
0.021) 0.06
-0.023 (-0.12,
0.17) 0.76
Adj Ca,
mg/dLa
0.011 (-0.011,
0.035) 0.03
0.005
(-0.018,
0.029)
0.66
0.0067
(-0.006,
0.020)
0.29
Vit-D,
nmol/La
-0.14 (-0.01,
0.29) 0.06
0.11 (-0.04,
0.26) 0.16
-0.040 (-0.13,
0.049) 0.38
PTH, ng/La 0.06 (-0.20,0.08) 0.39
-0.063 (-0.20,
0.082) 0.39
0.007 (-0.07,
0.09) 0.86
height or weight (Table 5). These findings were further
supported in the analyses stratified by SES where PO4 levels in
boys with lower SES were positively associated with child U-As
(Table 5). A positive association between U-As and plasma Ca
levels were observed in stunted boys only.
We also evaluated the impact of arsenic methylation
efficiency (pattern of urinary arsenic metabolites) on the
association between U-As and IGF-1. Since we found a
significantly higher concentration of %MMA (U-As metabolite)
in the high IGF-1 group (median split at 59 μg/L) compared to
the low IGF-1 group (Table 3), we additionally adjusted for % of
MMA. The estimates of the associations between U-As and
IGF-1 changed about 15% (Table S2 in File S1). Thereafter,
we stratified the analysis by %MMA (median split at 9.7%) and
an inverse association between U-As and IGF-1 was found in
all children with high %MMA. When further stratified by sex and
growth, the association was robust in girls (Table 6) particularly
those with normal height (Table S3 in File S1). Boys showed
no major impact of %MMA in urine, besides a slightly clearer
association between U-As and plasma PO4 in the high %MMA
group (Table 6).
As exposure and IGF-1 in neonates
Prenatal As exposure (maternal U-As at GW8 and GW30)
was inversely associated with plasma concentrations of IGF-1
in neonates at birth (r=-0.242, P=0.005 and r=-0.254, P=0.003
respectively). Multi-variable adjusted linear regression analysis
of maternal U-As at GW8 or GW30 showed a significantly
inverse association with IGF-1 levels in neonates (Figure 3).
Intriguingly, the significant association was evident in boys only
when stratified by sex.
Nutritional supplementation groups
We evaluated the effects of concurrent arsenic exposure on
plasma biomarkers at 4.5 years of age in different maternal
supplementation groups. There was a tendency of lower
plasma IGF-1 in relation to concurrent arsenic exposure in the
Table 4 (continued).
Variables U-As at 4.5 years (per 10 µg/L)
U-As at GW8 (per
10µg/L)
 Unadjusted Adjusted Adjusted
 β (95% CI) P β (95% CI) P β (95% CI) P
B-ALP, µg/La -0.005 (-0.37,0.38) 0.98
0.026 (-0.36,
0.41) 0.89
-0.12 (-0.34,
0.10) 0.28
PO4, mg/dLa
-0.016 (-0.06,
0.032) 0.51
-0.022
(-0.072,
0.026)
0.36 -0.004 (-0.03,0.024) 0.80
CI, confidence interval; β, unstandardized regression coefficients; U-As; urinary
arsenic ; IGF-1, insulin-like growth factor 1; Adj Ca, albumin adjusted calcium; Vit-
D, vitamin D; PTH, parathyroid hormone; B-ALP, bone-specific alkaline
phosphatase; PO4, phosphate. aAdjusted for SES, parity (birth order), child sex
(for all children) and HAZ. bAdjusted for SES, parity (birth order), child sex (for all
children), HAZ, and plasma levels of Adj Ca, Vit-D, PTH, B-ALP and PO4.
doi: 10.1371/journal.pone.0081530.t004
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Figure 2.  Associations between concurrent urinary arsenic (U-As) and plasma IGF-1 in 4.5 years children; (A) boys
(rs=-0.06; P=0.26), (B) girls (rs=-0.118; P=0.038).  Solid line indicates linear regression line and dashed line indicates Loess line.
doi: 10.1371/journal.pone.0081530.g002
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Table 5. Linear regression analysis of associations between concurrent arsenic exposure and plasma growth biomarkers in
4.5 yr old children in relation to growth retardation and socioeconomic status.
 U-As at 4.5 years (per 10 µg/L)
 Stunted (N=184) Adequate height (N=449) Underweight (N=247) Adequate weight (N=386) Low SES (N=323) High SES (N=312)
 β (95 % CI) β (95 % CI) β (95 % CI) β (95 % CI) β (95 % CI) β (95 % CI)
All children (N=640)
IGF-1 (µg/L)a -0.016 (-0.2, 0.23) -0.37 (-0.6, -0.05)* -0.15 (-0.4, 0.11) -0.30 (-0.6¸ 0.04) -0.11 (-0.3, 0.13) -0.46 (-0.89, -0.02)*
IGF-1 (µg/L)b 0.009 (-0.28, 0.3) -0.39 (-0.72, 0.07) -0.14 (-0.4, 0.17) -0.34 (-0.6¸ 0.005) -0.10 (-0.36, 0.16) -0.51 (-0.94, -0.07)*
Adj Ca (mg/dL) a -0.005 (-0.04¸0.03) 0.013 (-0.006, 0.03) 0.003 (-0.02, 0.03) 0.012 (-0.01, 0.03) 0.004 (-0.02, 0.02) 0.015 (-0.01¸ 0.04)
PO4 (mg/dL) a 0.054 (-0.01, 0.12) 0.002 (-0.05, 0.059) 0.092 (0.03, 0.14)* -0.034 (-0.09¸ 0.03) 0.045 (-0.01¸ 0.1) -0.035 (-0.10, 0.03)
Boys (N=328)
IGF-1 (µg/L) a 0.047 (-0.41¸ 0.51) -0.29 (-0.73, 0.15) -0.18 (-0.69, 0.31) -0.21 (-0.70,0 .27) 0.035 (-0.3, 0.38) -0.36 (-1.03, 0.31)
IGF-1 (µg/L) b 0.011 (-0.53, 0.55) -0.32 (-0.77¸0 .13) -0.12 (-0.70¸ 0.45) -0.23 (-0.73, 0.25) 0.028 (-0.33¸0.4) -0.47 (-1.16¸0.21)
Adj Ca (mg/dL) a 0.059 (-0.001, 0.1) -0.005 (-0.03¸ 0.02) 0.026 (-0.03, 0.08) 0.002 (-0.02, 0.03) 0.013 (-0.02, 0.04) 0.0014 (-0.040, 0.04)
PO4 (mg/dL) a 0.27 (0.089, 0.46)* 0.045 (-0.041, 0.13) 0.31 (0.21¸ 0.41)* -0.008 (-0.11, 0.09) 0.18 (0.06¸ 0.30)* -0.035 (-0.13¸ 0.062)
Girls (N=312)
IGF-1 (µg/L) a 0.035 (-0.35, 0.28) -0.51 (-0.9, -0.04)* -0.16 (-0.50¸0.17) -0.44 (-0.92, 0.03) -0.19 (-0.54, 0.15) -0.56 (-1.09, -0.03)*
IGF-1 (µg/L) b 0.0054 (-0.39, 0.4) -0.49 (-0.97¸-0.02)* -0.13 (-0.54¸0 .27) -0.47 (0.97¸ 0.01)* -0.18 (-0.58, 0.21) -0.55 (-1.1¸ -0.004)*
Adj Ca (mg/dL) a -0.03 (-0.07, 0.02) 0.026 (.002¸ .051)* -0.008 (-0.04, 0.03) 0.016 (-0.01, 0.04) -0.0062 (-0.03¸ 0.02) 0.033 (-0.007¸ 0.07)
PO4 (mg/dL) a 0.005 (-0.06¸0.069) -0.045 (-0.11, 0.02) 0.013 (-0.04¸ .007) -0.06 (-0.13¸ 0.014) -0.017 (-0.08, 0.04) -0.034 (-0.12¸ 0.055)
CI, confidence interval; β, unstandardized regression coefficients; U-As, urinary arsenic; SES, socioeconomic status; IGF-1, insulin-like growth factor 1; Adj Ca, albumin
adjusted calcium; Vit-D, vitamin D; PTH, parathyroid hormone; B-ALP, bone-specific alkaline phosphatase; PO4, phosphate. aAdjusted for SES, parity (birth order), child sex
(for all children). bAdjusted for SES, parity (birth order), child sex (for all children), and plasma levels of Adj Ca, Vit-D, PTH, B-ALP and PO4. * indicates P<0.05.
doi: 10.1371/journal.pone.0081530.t005
Figure 3.  Associations between maternal urinary arsenic at gestational week (GW) 8 and 30 with cord blood insulin-like
growth factor 1 (IGF-1) in all children, boys and girls.  The associations were adjusted with mother age, socioeconomic status
(SES), parity (birth order), child sex (for all children), and birth weight and height.
doi: 10.1371/journal.pone.0081530.g003
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60 mg Fe supplementation group (β= -0.543, P= 0.035). We
did not find any significant associations between concurrent
arsenic exposure and other plasma biomarkers in different
supplementation groups.
Discussion
In this study, we found that arsenic exposure was associated
with lower plasma IGF-1 in pre-school children. The effect was
more evident in girls, particularly adequately nourished girls,
than in boys. This finding is essential for our understanding of
the mode of action of the previously-reported impairments in
fetal and child growth associated with moderately elevated
arsenic exposure [6-8,15,16].
Table 6. Linear regression analysis of plasma biomarkers in
relation to concurrent arsenic exposure in 4.5 years old
children, boys and girls stratified by % of MMA (median
split, 9.7%).
Variables U-As at 4.5 years (per 10 µg/L)
 Low % of MMA High % of MMA
 β (95% CI) P β (95% CI) P
All children (N=640)
IGF-1, µg/La -0.12 (-0.48, 0.23) 0.58 -0.34(-0.62, -0.05) 0.02
IGF-1, µg/Lb -0.15 (-0.56, 0.27) 0.48 -0.36(-0.64, -0.07) 0.01
Adj Ca, mg/dLa 0.026 (-0.009, 0.06) 0.15 0.0006(-0.018, 0.019) 0.95
Vit-D, nmol/La 0.008 (-0.20, 0.21) 0.94 0.06 (-0.10, 0.22) 0.47
PTH, ng/La 0.013 (-0.21, 0.23) 0.90 -0.033 (-0.17, 0.11) 0.65
B-ALP, µg/La -0.10 (-0.62, 0.41) 0.69 0.17 (-0.18, 0.52) 0.35
PO4, mg/dLa 0.019 (-0.06, 0.10) 0.64 0.028 (-0.02, 0.07) 0.26
Boys (N=328)
IGF-1, µg/La -0.21 (-0.77, 0.35) 0.46 -0.25 (-0.70, 0.20) 0.28
IGF-1, µg/Lb -0.23 (-0.79, 0.34) 0.43 -0.37 (-0.84, 0.096) 0.11
Adj Ca, mg/dLa 0.028 (-0.01, 0.065) 0.15 -0.009 (-0.04, 0.02) 0.60
Vit-D, nmol/La -0.032 (-0.32, 0.26) 0.82 0.012 (-0.31, 0.34) 0.94
PTH, ng/La 0.047 (-0.31, 0.40) 0.79 0.088 (-0.16, 0.34) 0.49
B-ALP, µg/La 0.007 (-0.71, 0.73) 0.98 0.41 (-0.17, 0.99) 0.16
PO4, mg/dLa 0.086 (-0.049, 0.22) 0.21 0.089 (.0.003, .017) 0.04
Girls (N=312)
IGF-1, µg/La -0.042 (-0.51, 0.41) 0.85 -0.45 (-0.81, -0.08) 0.01
IGF-1, µg/Lb -0.017 (-0.67, 0.64) 0.95 -0.41 (-0.77, -0.036) 0.03
Adj Ca, mg/dLa 0.019 (-0.04, 0.08) 0.55 0.0034 (-0.019, 0.026) 0.76
Vit-D, nmol/La 0.049 (-0.25, 0.35) 0.75 0.079 (-0.096, 0.25) 0.37
PTH, ng/La -0.025 (-0.29, 0.24) 0.85 -0.08 (-0.26, 0.10) 0.38
B-ALP, µg/La -0.19 (-0.95, 0.56) 0.61 0.076 (-0.38, 0.54) 0.74
PO4, mg/dLa -0.046 (-0.13, 0.043) 0.31 -0.005 (-.0.064, 0.05) 0.85
CI, confidence interval; β, unstandardized regression coefficients; U-As; urinary
arsenic ; IGF-1, insulin-like growth factor 1; Adj Ca, albumin adjusted calcium; Vit-
D, vitamin D; PTH, parathyroid hormone; B-ALP, bone-specific alkaline
phosphatase; PO4, phosphate; MMA, monomethyl arsonic acid; SES,
socioeconomic status. aAdjusted for SES, parity (birth order), child sex (for all
children) and HAZ. bAdjusted for SES, parity (birth order), child sex (for all
children), HAZ, and plasma levels of Adj Ca, Vit-D, PTH, B-ALP and PO4.
doi: 10.1371/journal.pone.0081530.t006
The suppressive effects on child growth in the same but
larger cohort were stronger for concurrent exposure than for
prenatal exposure, and consistently affected growth in girls
more than in boys, particularly more in girls with higher SES
[8,15]. We also found similar arsenic related effects on child
IGF-1 in the present study. In utero arsenic exposure, on the
other hand, was associated with lower cord blood IGF-1
concentrations in boys (Figure 3), in accordance with our
previous reports on arsenic exposure and lower fetal size in
boys [6]. On average, boys had 12% lower IGF-1 than girls,
both at birth and at 4.5 years of age, which is in line with
previous findings [17,18] and is also supported by an earlier
study showing gender specificity of IGF-1 levels at term birth
[19]. Similarly, among healthy Turkish and Korean children of
the same age group as ours, IGF-1 levels in girls (162 and 160
μg/L, respectively) were generally higher than in boys (115 and
145 ug/L, respectively) [20,21]. It is particularly noteworthy that
IGF-1 levels of girls (72± 37 μg/L) and boys (64± 41 μg/L) in
our cohort were almost half of that of healthy children of the
same age group from resource rich countries such as Turkey
and Korea. Girls in general are more growth retarded than
boys, especially in developing countries. Similarly, girls in our
cohort are more stunted (33% vs 26%) and more underweight
(43% vs 36%) than boys. It may be assumed that in order to
compensate for the short stature of the girls, IGF-1 levels may
remain elevated during the rapidly growing years of childhood.
Other factors that are known to affect the levels of IGF-1
include genetics, stress, nutrition, body mass index, and
disease status, including xenobiotic intake [22]. To the best of
our knowledge, this is the first indication of adverse effects of
arsenic on child IGF-1. The finding is supported by in vitro
studies with differentiating C2C12 cells, which after exposure to
20 nM arsenic, showed epigenetic effects of altered histone
remodeling status on the myogenin promoter and impaired
protein and mRNA levels of IGF-1[23].
IGF-1 is a primary mediator of the effects of growth hormone
and plays an important role in childhood growth. As expected,
we found a strong positive association between plasma IGF-1
levels and height and weight. The majority of stunted and
underweight children in this study cohort were present in the
low IGF-1 group compared to the high IGF-1 group (stunted,
39% vs 19%, P<0.001; underweight, 44% vs 34%, P=0.012
respectively). In an earlier study, Fall et al showed higher
plasma concentrations of IGF-1 in children who were
underweight in utero[18]. We did not find any differences in the
IGF-1 levels between low birth weight and normal weight
children at birth or at 4.5 yrs of age. It is quite likely that arsenic
may re-program the effects of IGF-1 that consequently affects
fetal growth. However, further studies are needed to confirm
this postulation. Nutrition is an important determinant for child
growth; this may explain our finding of stronger associations
with elevated arsenic exposure in the girls with better nutrition
(normal height and weight) than in those with poor nutrition. It
is possible that in stunted and growth-retarded children, the
negative effects of As exposure on IGF-1 are masked by
multiple factors contributing to growth retardation, such as
recurrent infections, malnutrition, micronutrient deficiencies,
poverty, and stress, whereas in children with normal growth,
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the suppressive effects are more obvious. It was also not clear
why %MMA was higher in the high IGF group compared to the
low IGF group. One may assume that the toxic effects of higher
MMA levels in children may be compensated with higher
production of IGF-1.
Recent studies indicate that cord blood IGF-1 is a key
regulator of neonatal immune responses in maturation and
infection, particularly by suppressing pro-inflammatory Th1
responses [24]. Interestingly, we previously found that prenatal
arsenic exposure was associated with an increased incidence
of acute respiratory infections in male infants [25], and with
cold and cough later in childhood [8], possibly related to an
impaired thymus function [26]. Disregulation or disturbances of
IGF-1 levels in serum and its receptor may be linked with
susceptibility to infections and subsequent diseases in children.
IGF-1 signaling is important for linear and appositional bone
growth, bone mineralization [27] and bone accrual during the
postnatal growth phase [28]. An association between a
reduced plasma concentration of IGF-1 and the inhibition of
bone and muscle growth has been demonstrated in studies in
animals [29]. Bone tissue is also a target organ for arsenic
since it is an analog of PO4 [14,30,31]. Arsenic and phosphorus
are located in the same group of the periodic table, and arsenic
can compete with phosphorus in the oxidative phosphorylation
process that can lead to replacement of phosphorus in the
bone [9,32,33]. Indeed, we found elevated plasma PO4 levels
to be related to arsenic exposure in boys, particularly
malnourished boys. The potential consequences of this in
terms of bone health remain to be investigated.
One limitation of this study is the small sample size of the
neonatal cohort, resulting in low statistical power, especially
after stratifying the data by sex. In this study, there was a trend
for an inverse association between current arsenic exposure
and growth indicators; however, the association was not
significant. Probably, a much larger sample size is needed to
find a significant association between arsenic exposure and
anthropometric indicators as seen for children at birth and 2
years of age in the MINIMat cohort [8,15]. We did not find any
association between growth indices and plasma biomarkers
other than IGF-1.
In conclusion, our study showed that prenatal arsenic
exposure has suppressive effects on cord blood IGF-1 in boys
at birth, while childhood exposure impaired IGF-1 at 4.5 years
of age, particularly in girls, at an age when more girls were
stunted and underweight than boys. These findings may
explain, in part, the previously-reported gender-specific
impairment of arsenic exposure on fetal and child growth.
Further studies on growing children at pre-adolescent stages
are ongoing to better understand and decipher the role of
arsenic in child growth trajectory.
Materials and Methods
Ethics Statement
The study (Research Protocol # 2008-034) was approved by
the ethical review committee (ERC) of icddr,b on 7th August,
2008. Written informed consent was obtained from the
participating women and the parents/ guardians on behalf of
the children.
Study area and subjects
The study was conducted in Matlab, a rural riverine area
located 53 km southeast of Dhaka, Bangladesh. The
International Centre for Diarrhoeal Disease Research,
Bangladesh (icddr,b) runs a central hospital and four sub-
center clinics and maintains a Health and Demographic
Surveillance System (HDSS) in this area since 1966. Matlab is
extensively affected by arsenic contamination of drinking water.
A population-based survey in 2002-2003 measuring arsenic
concentrations in all functioning 13,286 tubewells in Matlab
found about 70% of the tube-wells installed during the last few
decades exceeding the WHO drinking water guidelines of 10
µg As/L [34,35].
Our ongoing research on effects of early-life arsenic
exposure [25,26,36] was nested in a large, randomized,
population-based food and multi-micronutrient supplementation
trial (MINIMat trial; ISRCTN 16581394), which evaluated
nutritional impacts on pregnancy outcomes and child health
[37]. We obtained maternal urine samples in early pregnancy
(average gestational week, GW8), late pregnancy (average
GW30, n=134) and cord blood at delivery. Field research
assistants collected information on socioeconomic status
(SES), parity, and tobacco use based on a set of structured
questionnaires given to the pregnant women during the
scheduled monthly home visits.
The present study included 640 children, born during
2003-2004, and followed-up at 4.5 years of age with both
anthropometry and growth biomarkers. In a subset (N=134) of
children we had data on growth markers at birth. This subset
included pregnant women who delivered singleton infants at
the central Matlab hospital or any of the four sub-center clinics
during early in the day (5:00 AM to 2:30 PM). This design was
due to the necessity to transport cord blood samples and
process them in the laboratory within working hours of the
same day. Birth weight was measured within 72 hours of
delivery using electronic scales (SECA pediatric scales, U.K.)
with precision of 10g. Infant length was measured using a
validated, locally-manufactured wooden length board, with
precision of 0.1 cm.
Fasting blood was collected from 4.5 years old children in the
sub-center clinics in trace element-free lithium-heparin tubes.
Body weight, in light clothing and bare feet, was measured to
the nearest 0.1 kg with a digital scale (TANITA HD -318, Tanita
Corporation, Japan). Height was measured to the nearest 0.1
cm with the use of a stadiometer Leicester Height Measure
(Seca 214, UK). Weight and height measurements were
converted to weight-for-age, height-for-age, and weight-for-
height Z-scores (SD scores). Stunting was defined as <-2 Z-
score for height-for-age and underweight was defined as <-2 Z-
score for weight-for-age [38] (http://www.who.int/childgrowth/
software/en/).
Information of the SES of the family was collected using a
wealth index that was based on information about household
assets, house construction materials, ownership of land,
source of income of the household and family characteristics
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such as parental education etc. The wealth index was
estimated by principal component analysis, producing a
weighted score [39]. Scores were categorized into quintiles,
with category 1 representing the poorest and category 5 the
richest. Due to limited power of the analysis, the SES scores
were divided into two groups on the basis of the median split.
Arsenic exposure
We measured concentrations of metabolites of inorganic As
in maternal urine (U-As; defined as the sum of inorganic
arsenic and its methylated forms, monomethyl arsonic acid
(MMA) and dimethylarsinic acid (DMA)), that reflects the
ingested dose of iAs from all sources [35]. The relative
fractions of urinary metabolites were used as markers of
arsenic methylation efficiency. Urinary As in early (GW8)
pregnancy was used as a marker of fetal exposure [40]. Urine
was collected into trace-element-free plastic cups, transferred
to 24 mL polyethylene bottles, and stored at -70°C. The urinary
arsenic concentrations in mothers and their children were
measured using high-performance liquid chromatography
online with hydride generation and inductively coupled plasma
mass spectrometry, as described previously [41,42]. For quality
control purposes, we analyzed NIES reference material (CRM
No.18, National Institute for Environmental Studies, Tsukuba
City, Japan) together with urine samples collected from
mothers and 4.5 years old children. The certified reference
value of DMA was 36 ± 9 µg/L (mean ± SD) and the DMA
concentration we obtained was 43 ± 1.7 µg/L in maternal urine
and 42 ± 1.2 µg/L in children. To compensate for variation in
dilution, urine samples were adjusted to the average specific
gravity (both for mothers and children, 1.012 g/mL), measured
by a digital refractometer (EUROMEX RD712 Clinical
Refractometer, Holland) [43].
Biomarkers of growth
Plasma was separated from blood cells by centrifugation and
plasma aliquot was stored at –80 °C. Plasma levels of IGF-1,
25-OH VD, B-ALP, and iPTH were measured using the Human
IGF-1 ELISA kit (Quantakine ELISA, R&D Systems, Inc.,
Minneapolis, MN), 25-hydroxy vitamin D EIA kit
(Immunodiagnostic Systems Ltd., Boldon, UK), Ostase BAP kit
(Immunodiagnostic Systems Ltd., Boldon, UK), and the PTH
Intact ELISA kit (DRG International Inc., USA), respectively,
according to the manufacturer’s instructions. All absorbance
were measured at 450 nm (reference 650 nm, wavelength
correction set at 540) using a microplate reader. The
concentrations were calculated based on the standard curves.
Ca in plasma was measured using the QuantiChrom calcium
assay kit (Bioassay Systems, Hayward, CA) and adjusted for
plasma albumin concentrations since about half of serum Ca is
bound to albumin [44]. Plasma albumin concentration was
determined by the ALB plus kit (Roche Diagnostics GmbH,
Mannheim, Germany) in the automated clinical chemistry
autoanalyzer (Hitachi 902, Hitachi Ltd, Tokyo, Japan). Bi-level
control serum of normal level and high level, Precinorm Protein
and Precipath Protein (Roche diagnostics GmbH) were used to
check both accuracy and precision for albumin. For B-ALP,
iPTH and Vitamin D, commercially available control serum from
the respective kit manufacturer was used. Co-efficient of
variation was 5.6% for IGF-1, 8.6% and 5.2% for Ca, 6.8% and
4.8% for BAP, 11.0% and 10.3% for PTH, 10.5% and 10.4% for
vitamin D, and 6.6% and 1.6% for albumin.
Statistical analysis
Statistical analyses were performed using the software
PASW 20.0 (SPSS Inc., Chicago, USA) and Stata/IC, version
12.0 (StataCorp, Texas, USA). Data distribution patterns were
evaluated by scatter plots, and normality and homogeneity of
variances were checked. Associations between arsenic
exposure (per 10 µg/L) (urinary arsenic metabolites) and
growth biomarkers were analyzed in multivariable-adjusted
regression models, controlling for potential confounders and
influencing factors. Confounders were identified from the
covariates (maternal age, height, weight, body mass index
(BMI), gestational age, parity/birth order, SES, tobacco
chewing, as well as sex, birth weight and size, WHZ, HAZ and
WAZ of the children) based on correlations (p < 0.2) with the
exposure (As) and/ or outcome, and were included in final
models when they changed the effect estimate for U-As on the
outcome by 5% or more. Mothers’ age, parity, SES and sex of
the baby, were included in the final models. Furthermore, IGF-1
was additionally adjusted by other plasma biomarkers. P-
values < 0.05 were considered significant.
In the sensitivity analysis, all plasma biomarkers were
adjusted for other plasma biomarkers.
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